AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it has received market approvals from the Taiwan Food and Drug Administration for its MINI WELL, MINI WELL PROXA, and MINI WELL TORIC intraocular lenses, as well as the monofocal intraocular lens MINI 4 Ready. These extended depth-of-focus (EDOF) lenses are designed for use in the surgical treatment of cataracts.
Features and Benefits of the Lenses
MINI WELL, MINI WELL PROXA, and MINI WELL TORIC are presbyopia correction intraocular lenses that provide patients with good vision, allowing for a natural transition from far, medium, and near distances after cataract surgery. This increases the depth of field when viewing objects. MINI WELL TORIC also corrects preoperative corneal astigmatism of 3.0D and below. These lenses represent the most advanced cataract refractive solutions available today, capable of correcting myopia, hyperopia, presbyopia, and corneal astigmatism. They help patients achieve postoperative lens removal and provide high-quality full-range vision under various light conditions.
Company Background and Focus
AffaMed Therapeutics is dedicated to developing and commercializing transformative pharmaceutical, digital, and surgical products that address critical unmet medical needs in ophthalmic, neurological, and psychiatric disorders for patients in Greater China and around the world. AffaMed Technologies specializes in the development, manufacturing, and sales of high-end intraocular lenses in Greater China.-Fineline Info & Tech
